EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Current state, challenges, unmet needs, and future directions in the pharmacological treatment of biliary tract cancer

Michael H Storandt, Amit Mahipal

Expert Review of Clinical Pharmacology · 2025

DOI: 10.1080/17512433.2025.2546149 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, 2025. Verfasst von Michael H Storandt und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Biliary Tract Neoplasms, Antineoplastic Agents, Molecular Targeted Therapy. Die Arbeit nennt 94 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: There has been a significant change in the treatment paradigm of biliary tract cancers (BTCs) in recent years with the introduction of chemoimmunotherapy and the development of targeted agents. In the present review, we describe the current landscape of systemic therapy for BTC and discuss forthcoming novel therapeutics. AREAS COVERED: We completed a narrative review using pertinent clinical trials discussing systemic therapy for BTC listed on PubMed, as well as ongoing trials included on clinicaltrials.gov. We discuss evidence for use of systemic therapy in the adjuvant setting and review first- and second-line systemic therapy, including targeted agents, for treatment of advanced BTC. EXPERT OPINION: Despite advances in systemic therapy for BTC, there is a high incidence of recurrence for resected diseases and the prognosis for metastatic diseases remains poor. Development and assessment of novel therapeutics will be essential going forward, as will research regarding means to overcome resistance mechanisms that limit efficacy of targeted agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biliary Tract NeoplasmsAntineoplastic AgentsMolecular Targeted TherapyHumansDrug DevelopmentPrognosisImmunotherapyNeoplasm Recurrence, LocalAnimalsDrug Resistance, NeoplasmChemotherapy, Adjuvant

Stichwörter der Autor:innen

Biliary tract cancerampullary cancerchemotherapycholangiocarcinomagallbladder carcinomaimmunotherapytargeted therapy

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
  • Department of Medical Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA.

Zitieren

APA

Storandt, M. H., & Mahipal, A. (2025). Current state, challenges, unmet needs, and future directions in the pharmacological treatment of biliary tract cancer. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2025.2546149

Vancouver

Storandt MH, Mahipal A. Current state, challenges, unmet needs, and future directions in the pharmacological treatment of biliary tract cancer. Expert Review of Clinical Pharmacology. 2025. doi:10.1080/17512433.2025.2546149

BibTeX
@article{Storandt2025,
  author = {Storandt, Michael H and Mahipal, Amit},
  title = {Current state, challenges, unmet needs, and future directions in the pharmacological treatment of biliary tract cancer},
  journal = {Expert Review of Clinical Pharmacology},
  year = {2025},
  doi = {10.1080/17512433.2025.2546149}
}
Kostenlos starten →